Centaur Pharmaceuticals & Kibow Biotech Announce a Strategic Alliance to Market Renadyl in India
Prevalence of Chronic Kidney Disease in India is 17.2% and rising Dialysis is a painful and expensive process with scarcely available resources This novel, US-patented, and clinically-tested product helps maintain healthy kidney functions by Shrutee K/DNS Mumbai, 06 March, 2018 : Centaur Pharmaceuticals and Kibow Biotech USA announced a strategic long-term alliance to market Renadyl in India. Centaur will initially import and market the product in India, and will eventually manufacture and market with technical inputs from Kibow Biotech. In an opening address Mr Gregory Taevs thanked Centaur and Kibow for inviting him to the occasion & wished the strategic alliance a grand success. Commenting on this strategic alliance, Dr Natrajan Ranganathan, Ph.D. (Bio-organic Chemistry), inventor of the globally patented product, and the Founder and Managing Director of Kibow Biotech, said, “As my roots are from India, I am extremely happy that my company Kibow Bio...